Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185

1.

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer.

Simonetti S, Molina MA, Queralt C, de Aguirre I, Mayo C, Bertran-Alamillo J, Sanchez JJ, Gonzalez-Larriba JL, Jimenez U, Isla D, Moran T, Viteri S, Camps C, Garcia-Campelo R, Massuti B, Benlloch S, Ramon y Cajal S, Taron M, Rosell R.

J Transl Med. 2010 Dec 18;8:135. doi: 10.1186/1479-5876-8-135.

2.

Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.

Kawahara A, Azuma K, Sumi A, Taira T, Nakashima K, Aikawa E, Abe H, Yamaguchi T, Takamori S, Akiba J, Kage M.

Lung Cancer. 2011 Oct;74(1):35-40. doi: 10.1016/j.lungcan.2011.02.002.

PMID:
21444121
3.
5.

Novel epidermal growth factor receptor mutation-specific antibodies for non-small cell lung cancer: immunohistochemistry as a possible screening method for epidermal growth factor receptor mutations.

Kato Y, Peled N, Wynes MW, Yoshida K, Pardo M, Mascaux C, Ohira T, Tsuboi M, Matsubayashi J, Nagao T, Ikeda N, Hirsch FR.

J Thorac Oncol. 2010 Oct;5(10):1551-8. doi: 10.1097/JTO.0b013e3181e9da60.

6.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
7.

Comparison of epidermal growth factor receptor mutation statuses in tissue and plasma in stage I-IV non-small cell lung cancer patients.

Zhao X, Han RB, Zhao J, Wang J, Yang F, Zhong W, Zhang L, Li LY, Wang MZ.

Respiration. 2013;85(2):119-25. doi: 10.1159/000338790.

PMID:
22797485
8.

Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.

Kawahara A, Yamamoto C, Nakashima K, Azuma K, Hattori S, Kashihara M, Aizawa H, Basaki Y, Kuwano M, Kage M, Mitsudomi T, Ono M.

Clin Cancer Res. 2010 Jun 15;16(12):3163-70. doi: 10.1158/1078-0432.CCR-09-3239.

9.

The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.

Kozu Y, Tsuta K, Kohno T, Sekine I, Yoshida A, Watanabe S, Tamura T, Yokota J, Suzuki K, Asamura H, Furuta K, Tsuda H.

Lung Cancer. 2011 Jul;73(1):45-50. doi: 10.1016/j.lungcan.2010.11.003.

PMID:
21129809
10.

EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.

Cooper WA, Yu B, Yip PY, Ng CC, Lum T, Farzin M, Trent RJ, Mercorella B, Clarkson A, Kohonen-Corish MR, Horvath LG, Kench JG, McCaughan B, Gill AJ, O'Toole SA.

J Clin Pathol. 2013 Sep;66(9):744-8. doi: 10.1136/jclinpath-2013-201607.

PMID:
23757037
11.

Immunostaining with EGFR mutation-specific antibodies: a reliable screening method for lung adenocarcinomas harboring EGFR mutation in biopsy and resection samples.

Fan X, Liu B, Xu H, Yu B, Shi S, Zhang J, Wang X, Wang J, Lu Z, Ma H, Zhou X.

Hum Pathol. 2013 Aug;44(8):1499-507. doi: 10.1016/j.humpath.2012.12.002.

PMID:
23465272
12.

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.

Riely GJ, Pao W, Pham D, Li AR, Rizvi N, Venkatraman ES, Zakowski MF, Kris MG, Ladanyi M, Miller VA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44.

13.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
14.

Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction.

Wu SG, Chang YL, Lin JW, Wu CT, Chen HY, Tsai MF, Lee YC, Yu CJ, Shih JY.

PLoS One. 2011;6(8):e23303. doi: 10.1371/journal.pone.0023303.

15.

[Detection of EGFR gene mutations in 100 non-small cell lung cancer clinical samples by a real-time polymerase chain reaction method using amplification refractory mutation system specific primers and Taqman fluorescence probes].

Zhao J, Zhao J, Zhao X, Chen W, Zhong W, Zhang L, Li L, Wang M.

Zhongguo Fei Ai Za Zhi. 2013 Jan;16(1):25-32. doi: 10.3779/j.issn.1009-3419.2013.01.05. Chinese.

16.

Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.

Yu J, Kane S, Wu J, Benedettini E, Li D, Reeves C, Innocenti G, Wetzel R, Crosby K, Becker A, Ferrante M, Cheung WC, Hong X, Chirieac LR, Sholl LM, Haack H, Smith BL, Polakiewicz RD, Tan Y, Gu TL, Loda M, Zhou X, Comb MJ.

Clin Cancer Res. 2009 May 1;15(9):3023-8. doi: 10.1158/1078-0432.CCR-08-2739.

17.

L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.

Sasaki H, Endo K, Takada M, Kawahara M, Kitahara N, Tanaka H, Okumura M, Matsumura A, Iuchi K, Kawaguchi T, Yukiue H, Kobayashi Y, Yano M, Fujii Y.

Lung Cancer. 2006 Oct;54(1):103-8.

PMID:
16890322
18.

Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.

Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M, Kusumoto M, Yamamoto S, Yoshida T, Tamura T.

Clin Cancer Res. 2008 Aug 1;14(15):4751-7. doi: 10.1158/1078-0432.CCR-07-5207.

19.

Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.

Won YW, Han JY, Lee GK, Park SY, Lim KY, Yoon KA, Yun T, Kim HT, Lee JS.

J Clin Pathol. 2011 Nov;64(11):947-52. doi: 10.1136/jclinpath-2011-200169.

PMID:
21725039
20.

Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.

Kanaji N, Bandoh S, Ishii T, Kushida Y, Haba R, Kohno K, Dobashi H, Ohnishi H, Matsunaga T.

Mol Diagn Ther. 2011 Dec 1;15(6):353-9. doi: 10.2165/11595700-000000000-00000.

PMID:
22117119
Items per page

Supplemental Content

Support Center